Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars

Executive Summary

Innovators are using increasingly complicated tactics in the high-stakes game of keeping biosimilars at bay to ensure their brand-name medicines can keep hauling in the cash for as long as possible.


Related Content

Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Pfizer/Celltrion Prep For October Inflectra Launch
Tentative-Style Approvals Coming For US Biosimilars?
Congress Last Resort On IPRs After Supreme Court Backs Patent Board
AbbVie Foe Coherus Sways PTAB To Review Humira Patent
BIO: Deals, Investment At Risk If IPR Course Unchanged
Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts
Lawsuit: Sandoz Copycat Piggybacks Enbrel, Ducks Duties
1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing


Related Companies